drugset / Trial / NCT06677801
Immune Cell Subsets in SLE Patients Treated with Telitacicept
Phase 4
Active not recruiting
50 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelDiagnostic
Summary
This study is a single-center cohort study. Patients with SLE who met the inclusion criteria were treated with tetanercept 160 mg once a week for a total of 24 weeks, and the clinical and laboratory indicators were collected before treatment, at the 4th week, at the 12th week, and at the 24th week, and blood samples were collected for the detection of immune cell subsets.
Timeline
- Start
- 2024-10-11
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Telitacicept | Protein / enzyme biologic | 160 mg | — |